A509 loss by 94, 76 and 87% respectively. The cost per case avoided would be 165 Euros, and cost per hospitalization avoided would be 1,639 Euros with implementation of universal vaccination. The cost per QALY saved would be 29,452 Euros and 20,453 Euros from the health care and societal perspectives respectively. ConClusions: RV5 is projected to avert substantial number of RGE hospitalizations and office visits in Slovenia and would be considered a cost effective intervention.
A631score. Results: Mean DMC per QoL was lowest in Pr, and highest in Hem cancers (ranged 60.1-195.1 TL/global QoL score) (Pr< Gy< CR≈Gas≈Br≈Lng≈H&N< Hem). QoL was lowest in Gy and highest in CR (ranged 53,1-65,2) (Gy< Lng< Pr< Br≈Hem≈H&NC). Total DMC ranged from 3124-13557 TL (Pr≈GY< Br< Gas≈CR< Lng≈H&N< Hem). Depending on the type of the cancer the association between DMC and QoL could be in different directions (the correlation between DMC and role functioning was positive in Gas, while it was negative in H&N cancer). ConClusions: For a fixed period of time the total DMC associated with the management of different types of cancers vary substantially. As expected the total cost does not however purchase equal amount of QoL for each type of cancer. For those cancers with higher DMC per QoL, we should consider implementing wider psychosocial support measures. Depending on the type of cancer DMC may reflect disease progression leading to decreased QoL, or it may reflect presence of an effective and aggressive management leading to increased QoL. PCN100 Cost-EffECtivENEss ModEl of PErtuzuMab iN CoMbiNatioN with trastuzuMab aNd doCEtaxEl CoMParEd with trastuzuMab iN CoMbiNatioN with doCEtaxEl for thE 1st liNE trEatMENt of hEr2+ MEtastatiC brEast CaNCEr iN ColoMbia
A595 over a 10-year horizon. A National Health Service (NHS) and personal social services perspective was considered. The effectiveness of treatment was evaluated in terms of Quality Adjusted Life Years (QALYs) and Disability Adjusted Life Years (DALYs). Data were sourced from a phase II, placebo controlled trial of bedaquiline, NHS reference costs, and the literature. Costs and effectiveness were discounted at a rate of 3.5% per annum. Probabilistic and deterministic sensitivity analysis was conducted. Results: The total discounted cost per patient on B+BR was £107,123, compared with £116,616 for BR. The total discounted QALYs per patient were 4.85 for B+BR and 3.81 for BR. The addition of bedaquiline to BR resulted in cost-savings of £9,493 and an additional 1.04 QALYs pp over a 10-year period, and is therefore considered to be the dominant (less costly and more effective) strategy over BR. B+BR remained dominant versus BR in the majority of sensitivity analyses, with a 74% probability of being dominant versus BR in the probabilistic analysis. ConClusions: In the UK, bedaquiline is likely to be cost-effective and cost-saving, compared to the current standard of care for MDR-TB under a range of scenarios. Cost-savings over a 10 year period were realized from reductions in lengths of hospital stay, which offset bedaquiline drug costs. Bedaquiline remained cost-saving in several sensitivity analyses, highlighting the certainty surrounding the results of the model. These results also indicate that the B+BR regimen can provide significant social economic benefits versus the BR only regimen.objeCtives: To evaluate the long-term cost-effectiveness of umeclidinium bromide 62.5 mcg OD (UMEC) compared to tiotropium bromide 18 mcg OD (TIO) for the maintenance treatment of COPD from the UK National Health Service perspective Methods: We utilized a recently developed, internally and externally validated linked equations COPD Cohort disease progression model. The treatment effect, expressed as change from baseline in forced expiratory volume in one second (FEV1) at 12 and 24 weeks estimated from a Bucher method indirect treatment comparison (ITC) analysis following a systematic review. UMEC price was set at parity price of £33.5/month to TIO. Model outcomes included exacerbations, life years, quality adjusted life years (QALYs) and costs/QALY. The time horizons investigated ranged from one to 20 years (lifetime) on a sliding one-year increment. Costs, survival, and QALYs after the first year were discounted at a rate of 3.5%. Health care costs were obtained from NHS reference costs . Sensitivity analyses were performed to evaluate the robustness of the model to variations in the underlying input parameters and assumptions. Results: The ITC estimated change from baseline in trough FEV1 of 18.06mL (95%CI: -19.11, 55.23, p= 0.341) at 12 weeks and 3.97mL (95%CI: -38.30, 46.25, p= 0.854) at 24 weeks for UMEC compared with TIO. At price parity, UMEC dominated TIO with incremental QALY of 0.0009, incremental life years of 0.0001 an...
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.